Granocyte (Lenograstim)

Granocyte is indicated for several hematologic conditions where neutrophil counts are compromised.

• Management of chemotherapy‑induced neutropenia to reduce infection risk.
• Treatment of neutropenia following allogeneic or autologous bone‑marrow transplantation.
• Mobilization of peripheral blood stem cells for collection prior to transplantation.
• Support of neutrophil recovery in patients receiving high‑dose radiation therapy.

Adverse reactions to lenograstim are generally mild to moderate, but serious events can occur.

Common

• Bone pain, especially in the lower back or hips.
• Mild fever or flu‑like symptoms.
• Injection site erythema or discomfort.
• Nausea or mild gastrointestinal upset.

Serious

• Splenic rupture or enlargement.
• Acute respiratory distress syndrome (ARDS).
• Severe allergic reactions such as anaphylaxis.
• Capillary leak syndrome.

When prescribing Granocyte, clinicians should evaluate patient history and monitor for specific safety concerns.

• Assess baseline neutrophil counts and overall bone‑marrow function before initiation.
• Use caution in patients with a history of splenic disorders or abdominal trauma.
• Avoid in individuals with known hypersensitivity to lenograstim or any excipients.
• Monitor for signs of infection, fever, or unexpected inflammation during therapy.
• Consider dose adjustment or discontinuation if severe bone pain or systemic reactions develop.
• Pregnancy and lactation status should be reviewed, as safety data are limited.

Lenograstim may interact with other medications or clinical conditions that affect immune function or hematopoiesis.

Avoid

• Concurrent use of other granulocyte colony‑stimulating factors or high‑dose corticosteroids without specialist guidance.
• Live vaccines administered during treatment, due to altered immune response.

Use with caution

• Chemotherapeutic agents that cause profound myelosuppression, requiring close monitoring of blood counts.
• Anticoagulants, as changes in platelet function may occur.
• Immunosuppressive biologics, which could modify the efficacy of neutrophil recovery.